# Emavusertib

Source: https://onco.cc/drugs/emavusertib/  
OnCo record `emavusertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.

## Summary

Emavusertib is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Curis, Inc., in chronic lymphocytic leukaemia, brain and spinal cord tumours. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: CA-4948
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Sources

- ClinicalTrials.gov: trials of Emavusertib: https://clinicaltrials.gov/search?intr=Emavusertib

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- companies: [Curis](https://onco.cc/companies/curis/)
- trials: [A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies](https://onco.cc/trials/nct07271667/), [CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)](https://onco.cc/trials/nct03328078/)

---
JSON: https://onco.cc/api/v1/entities/emavusertib.json